CDK46estäjä

CDK46estäjä refers to a class of drugs known as cyclin-dependent kinase 4 and 6 inhibitors. These inhibitors are a type of targeted cancer therapy. Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) are enzymes that play a crucial role in the cell cycle, specifically in the progression from the G1 phase to the S phase, which is necessary for cell division and proliferation. In many types of cancer, these kinases are overactive, leading to uncontrolled cell growth.

CDK46estäjä work by blocking the activity of CDK4 and CDK6. By inhibiting these enzymes, the drugs prevent cancer cells from dividing and growing, effectively slowing down or stopping tumor progression. These medications are particularly important in the treatment of certain types of breast cancer, especially hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. They are often used in combination with endocrine therapy, such as aromatase inhibitors or fulvestrant.

The development of CDK46estäjä has represented a significant advancement in the management of HR+/HER2- metastatic breast cancer, offering improved progression-free survival and overall survival for patients. Clinical trials have demonstrated their efficacy in various patient populations. Common side effects can include low blood cell counts (neutropenia), fatigue, nausea, and diarrhea. Regular monitoring of blood counts is typically required during treatment. Several CDK46estäjä are approved and widely used in clinical practice.